| ||||||||
| | | | 1 | | | ||
| | | | | 1 | | | |
| | | | | 7 | | | |
| | | | | 8 | | | |
| | | | | 12 | | | |
| | | | | 13 | | | |
| | | | | 21 | | | |
| | | | | 23 | | | |
| | | | | 25 | | | |
| | | | | | | ||
| | | | | | | ||
| | | | | | | ||
| | | | | | | ||
| | | | | | | ||
| | | | | | | ||
| | | | | 67 | | | |
| | | | | A-1 | | |
Name | | Age | | Position(s) | | Class | | Term Expires | | | Age | | Position(s) | | Class | | Term Expires | | ||||||||
Stuart A. Arbuckle | | 57 | | Director | | I | | 2024 | | | 58 | | Director | | I | | 2024 | | ||||||||
Camille L. Bedrosian, M.D.(1)(3) | | 70 | | Director | | III | | 2023 | | | 71 | | Director | | III | | 2026 | | ||||||||
Jennifer Good | | 58 | | Director | | II | | 2025 | | | 59 | | Director | | II | | 2025 | | ||||||||
Christophe R. Jean(2) | | 67 | | Director | | I | | 2024 | | | 68 | | Director | | I | | 2024 | | ||||||||
Edward T. Mathers(3) | | 63 | | Lead Director | | II | | 2025 | | | 64 | | Lead Director | | II | | 2025 | | ||||||||
David W. J. McGirr(2)(3) | | 68 | | Director | | III | | 2023 | | | 69 | | Director | | III | | 2026 | | ||||||||
David P. Meeker, M.D. | | 68 | | Director, Chairman of the Board | | III | | 2023 | | | 69 | | Director, Chairman of the Board | | III | | 2026 | | ||||||||
Lynn A. Tetrault, J.D.(1) | | 60 | | Director | | I | | 2024 | | | 61 | | Director | | I | | 2024 | |
| Board Diversity Matrix (As of April | | ||||||||||||
| Total Number of Directors | | | 8 | |
| | Female | | Male | | Non-Binary | | Did Not Disclose Gender | | | Female | | Male | | Non-Binary | | Did Not Disclose Gender | | ||||||||||||||||||||||||||||||||
Part I: Gender Identity | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | ||||||||
Directors | | | | 3 | | | | | 5 | | | | | 0 | | | | | 0 | | | | | | 3 | | | | | 5 | | | | | 0 | | | | | 0 | | | ||||||||
Part II: Demographic Background | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | ||||||||
African American or Black | | | | 0 | | | | | 0 | | | | | 0 | | | | | 0 | | | | | | 0 | | | | | 0 | | | | | 0 | | | | | 0 | | | ||||||||
Alaskan Native or Native American | | | | 0 | | | | | 0 | | | | | 0 | | | | | 0 | | | | | | 0 | | | | | 0 | | | | | 0 | | | | | 0 | | | ||||||||
Asian | | | | 0 | | | | | 0 | | | | | 0 | | | | | 0 | | | | | | 0 | | | | | 0 | | | | | 0 | | | | | 0 | | | ||||||||
Hispanic or Latinx | | | | 0 | | | | | 0 | | | | | 0 | | | | | 0 | | | | | | 0 | | | | | 0 | | | | | 0 | | | | | 0 | | | ||||||||
Native Hawaiian or Pacific Islander | | | | 0 | | | | | 0 | | | | | 0 | | | | | 0 | | | | | | 0 | | | | | 0 | | | | | 0 | | | | | 0 | | | ||||||||
White | | | | 3 | | | | | 5 | | | | | 0 | | | | | 0 | | | | | | 3 | | | | | 5 | | | | | 0 | | | | | 0 | | | ||||||||
Two or More Races or Ethnicities | | | | 0 | | | | | 0 | | | | | 0 | | | | | 0 | | | | | | 0 | | | | | 0 | | | | | 0 | | | | | 0 | | | ||||||||
LGBTQ+ | | 0 | | | | | | | | | | | | | | | 0 | | | | | | | | ||||||||||||||||||||||||||
Did Not Disclose Demographic Background | | 0 | | | | | | | | | | | | | | | 0 | | | | | | | |
Name: | | | Governance and Nominating Committee | | | Compensation & Management Development Committee | | | Audit Committee | |
Stuart A. Arbuckle | | | | | | X | | | | |
Camille L. Bedrosian, M.D. | | | X | | | X | | | | |
Jennifer Good | | | | | | | | | X | |
Christophe R. Jean | | | | | | | | | X | |
Edward T. Mathers | | | X* | | | | | | | |
David W. J. McGirr | | | X | | | | | | X* | |
Lynn A. Tetrault, J.D. | | | | | | X* | | | | |
Non-Employee Director | | | Annual Fee | | |||
Lead Director | | | | $ | 35,000 | | |
Non-Executive Chair | | | | $ | 30,000 | | |
Chair of the Audit Committee | | | | $ | 20,000 | | |
Member of the Audit Committee (other than chair) | | | | $ | 10,000 | | |
Chair of the Compensation & Management Development Committee | | | | $ | 15,000 | | |
Member of the Compensation & Management Development Committee (other than chair) | | | | $ | 7,500 | | |
Chair of the Governance and Nominating Committee | | | | $ | 10,000 | | |
Member of the Governance and Nominating Committee (other than chair) | | | | $ | 5,000 | | |
Name | | Fees Earned or Paid in Cash ($)(1) | | Option Awards ($)(2) | | Total ($) | | | Fees Earned or Paid in Cash ($)(1) | | Stock Awards ($)(2) | | Option Awards ($)(2) | | Total ($) | | ||||||||||||||||||||||||||||
Stuart Arbuckle | | | | 65,000 | | | | | 53,400 | | | | | 118,400 | | | | | | 67,500 | | | | | 55,410 | | | | | 178,360 | | | | | 301,270 | | | |||||||
Camille Bedrosian, M.D. | | | | 56,250 | | | | | 53,400 | | | | | 109,650 | | | | | | 62,500 | | | | | 55,410 | | | | | 178,360 | | | | | 296,270 | | | |||||||
Jennifer Good | | | | 47,500 | | | | | 53,400 | | | | | 100,900 | | | | | | 50,000 | | | | | 55,410 | | | | | 178,360 | | | | | 283,770 | | | |||||||
Christophe R. Jean | | | | 57,500 | | | | | 53,400 | | | | | 110,900 | | | | | | 60,000 | | | | | 55,410 | | | | | 178,360 | | | | | 293,770 | | | |||||||
Edward T. Mathers | | | | 92,500 | | | | | 53,400 | | | | | 145,900 | | | | | | 95,000 | | | | | 55,410 | | | | | 178,360 | | | | | 328,770 | | | |||||||
David W. J. McGirr | | | | 72,500 | | | | | 53,400 | | | | | 125,900 | | | | | | 75,000 | | | | | 55,410 | | | | | 178,360 | | | | | 308,770 | | | |||||||
Lynn A. Tetrault | | | | 62,500 | | | | | 53,400 | | | | | 115,900 | | | | | | 65,000 | | | | | 55,410 | | | | | 178,360 | | | | | 298,770 | | |
Name | | | Option Awards Outstanding at 2023 Fiscal Year End | | | Unvested Stock Awards Outstanding at 2023 Fiscal Year End | | ||||||
Stuart Arbuckle | | | | | 97,500 | | | | | | 3,000 | | |
Camille Bedrosian, M.D. | | | | | 86,000 | | | | | | 3,000 | | |
Jennifer Good | | | | | 97,500 | | | | | | 3,000 | | |
Christophe R. Jean | | | | | 92,500 | | | | | | 3,000 | | |
Edward T. Mathers | | | | | 92,500 | | | | | | 3,000 | | |
David W. J. McGirr | | | | | 179,741 | | | | | | 3,000 | | |
Lynn A. Tetrault | | | | | 86,000 | | | | | | 3,000 | | |
Name | | | Age | | | Position(s) | |
David P. Meeker, M.D. | | | | | Chairman of the Board, President and Chief Executive Officer | | |
Hunter C. Smith | | | | | Chief Financial Officer and Treasurer | | |
Pamela Cramer | | | | | Chief Human Resources Officer | | |
Joseph Shulman | | | | | Chief Technical Officer | | |
Jennifer | | | | | Executive Vice President, Head of North America | | |
Yann Mazabraud | | | | | Executive Vice President, Head of International | |
| What We Do | | | What We Do Not Do | | ||||||
| ✓ | | | Emphasize performance-based, | | | X | | | Do not grant guaranteed salary, bonus or equity compensation. | |
| ✓ | | | Emphasize the use of equity compensation to promote executive | | | X | | | Do not provide | |
| ✓ | | | Weight the overall pay mix towards incentive compensation for senior executives. | | | X | | | Do not provide any | |
| ✓ | | | Engage an independent compensation consultant to advise our Compensation & Management Development Committee. | | | X | | | Do not reprice stock option awards issued under our 2017 Equity Incentive Plan without stockholder approval. | |
| ✓ | | | Engage with shareholders to understand views on executive compensation | | | | ||||
| ✓ | | | Maintain a NASDAQ-compliant clawback policy. | | | X | | | Do not provide excessive severance payments. | |
| ✓ | | | Maintain an Insider Trading policy, including anti-hedging and anti-pledging provisions. | | | X | | | Do not provide supplemental executive retirement plans. | |
| ✓ | | | Maintain an independent Compensation & Management Development Committee. | | | | | | | |
| ✓ | | | Set challenging corporate performance goals. Maintain an industry-specific and size-appropriate compensation peer group for benchmarking compensation. | | | | | | | |
| ✓ | | | Conduct annual compensation risk assessment | | | | | | | |
| ✓ | | | Utilize an annual incentive plan with pre-set corporate goals and capped payouts | | | | | | | |
| ✓ | | | Maintain an annual say-on-pay vote frequency | | | | | | | |
| |||||||||||
Akebia | |||||||||||
| | Radius Health | | | |||||||
| | ||||||||||
| | | | |
|
| Amicus Therapeutics | | | BioCryst Pharmaceuticals | | | Ultragenyx Pharmaceuticals | |
| Agios Pharmaceuticals | | | Cara Therapeutics | | | Global Blood Therapeutics | | | Rigel Pharmaceuticals | |
| Albireo Pharma | | | ChemoCentryx | | | Insmed | | | TG Therapeutics | |
| Amicus Therapeutics | | | Deciphera Pharmaceuticals | | | Intra-Cellular Therapies | | | Travere Therapeutics | |
| Apellis Pharmaceuticals | | | Esperion Therapeutics | | | Karyopharm Therapeutics | | | Ultragenyx Pharmaceutical | |
| BioCryst Pharmaceuticals | | | G1 Therapeutics | | | |||||
Ocular Therapeutix | | | Vericel | |
Name | | | Base Salary ($) | | |||
David P. Meeker | | | | | | | |
Hunter C. Smith | | | | | | | |
Jennifer | | | | | | | |
Yann Mazabraud | | | | | | | |
Joseph Shulman | | | | | | |
Name | | | (as a percentage of base salary) | | |||
David P. Meeker | | | | | 65% | | |
Hunter C. Smith | | | | | 40% | | |
Jennifer | | | | | 40% | | |
Yann Mazabraud | | | | | 40% | | |
Joseph Shulman | | | | | 40% | | |
Named Executive Officer | | 2022 Target Bonus | | Actual 2022 Bonus Payout | | | 2023 Target Bonus | | Actual 2023 Bonus Payout | | ||||||||||||||||
David P. Meeker | | | $ | 423,833 | | | | $ | 505,420 | | | | | $ | 466,216 | | | | $ | 634,053 | | | ||||
Hunter C. Smith | | | $ | 184,000 | | | | $ | 217,000 | | | | | $ | 192,000 | | | | $ | 261,000 | | | ||||
Jennifer Chien | | | $ | 172,000 | | | | $ | 202,000 | | | |||||||||||||||
Jennifer Lee | | | $ | 189,200 | | | | $ | 246,000 | | | |||||||||||||||
Yann Mazabraud | | | $ | 172,000 | | | | $ | 202,697 | | | | | $ | 185,330 | | | | $ | 238,688 | | | ||||
Joseph Shulman | | | $ | 164,000 | | | | $ | 186,000 | | | | | $ | 174,000 | | | | $ | 226,000 | | |
Name | | Number of Shares Underlying Stock Options | | Number of RSUs | | | Number of Shares Underlying Stock Options | | Number of RSUs | | ||||||||||||||||
David P. Meeker | | | | 510,000 | | | | | — | | | | | | 229,600 | | | | | 56,500 | | | ||||
Hunter C. Smith | | | | 97,500 | | | | | 16,250 | | | | | | 53,600 | | | | | 19,700 | | | ||||
Jennifer Chien | | | | 82,500 | | | | | 13,750 | | | |||||||||||||||
Jennifer Lee | | | | 46,900 | | | | | 18,050 | | | |||||||||||||||
Yann Mazabraud | | | | 82,500 | | | | | 13,750 | | | | | | — | | | | | 41,500 | | | ||||
Joseph Shulman | | | | 63,750 | | | | | 10,625 | | | | | | 33,500 | | | | | 15,750 | | |
Name | | | Number of Vested PSUs | | |||
David P. Meeker | | | | | 99,000 | | |
Hunter C. Smith | | | | | 33,750 | | |
Jennifer Lee | | | | | 33,750 | | |
Yann Mazabraud | | | | | 33,750 | | |
Joseph Shulman | | | | | 33,750 | | |
Name and Principal Position | | Year | | Salary ($) | | Bonus ($) | | Stock Awards ($)(1) | | Option Awards ($)(2) | | Non-Equity Incentive Plan Compensation ($)(3) | | All Other Compensation ($)(4) | | Total | | | Year | | Salary ($) | | Stock Awards ($)(1) | | Option Awards ($)(2) | | Non-Equity Incentive Plan Compensation ($)(3) | | All Other Compensation ($)(4) | | Total ($) | | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
David P. Meeker Chief Executive Officer | | | | | 2022 | | | | | 652,050 | | | | | — | | | | | — | | | | | 2,157,300 | | | | | 505,420 | | | | | 10,988 | | | | | 3,325,758 | | | | | | | 2023 | | | | | 704,715 | | | | | 1,545,275 | | | | | 4,334,521 | | | | | 634,053 | | | | | 11,893 | | | | | 7,230,457 | | | |||||||||||||
| | | 2021 | | | | | 630,000 | | | | | — | | | | | 1,164,842 | | | | | 4,204,200 | | | | | 450,954 | | | | | 8,364 | | | | | 6,458,360 | | | | | | 2022 | | | | | 652,050 | | | | | — | | | | | 2,157,300 | | | | | 505,420 | | | | | 10,988 | | | | | 3,325,758 | | | ||||||||||||||||
| | | 2020 | | | | | 262,308 | | | | | — | | | | | 918,500 | | | | | 12,844,897 | | | | | 207,958 | | | | | 43,704 | | | | | 14,277,367 | | | | | | 2021 | | | | | 630,000 | | | | | 1,164,842 | | | | | 4,204,200 | | | | | 450,954 | | | | | 8,364 | | | | | 6,458,360 | | | ||||||||||||||||
Hunter C. Smith Chief Financial Officer | | | | | 2022 | | | | | 460,000 | | | | | — | | | | | 110,500 | | | | | 412,425 | | | | | 217,000 | | | | | 15,200 | | | | | 1,215,125 | | | | | | | 2023 | | | | | 476,154 | | | | | 538,795 | | | | | 1,011,892 | | | | | 261,000 | | | | | 20,166 | | | | | 2,308,007 | | | |||||||||||||
| | | 2021 | | | | | 435,957 | | | | | — | | | | | 576,264 | | | | | 1,074,938 | | | | | 210,654 | | | | | 11,600 | | | | | 2,309,412 | | | | | | 2022 | | | | | 460,000 | | | | | 110,500 | | | | | 412,425 | | | | | 217,000 | | | | | 15,200 | | | | | 1,215,125 | | | ||||||||||||||||
| | | 2020 | | | | | 416,118 | | | | | 60,000 | | | | | 132,000 | | | | | 1,837,630 | | | | | 209,595 | | | | | 7,125 | | | | | 2,662,468 | | | | | | 2021 | | | | | 435,957 | | | | | 576,264 | | | | | 1,074,938 | | | | | 210,654 | | | | | 11,600 | | | | | 2,309,413 | | | ||||||||||||||||
Jennifer Chien Executive Vice President, Head of North America | | | | | 2022 | | | | | 430,000 | | | | | — | | | | | 93,500 | | | | | 348,975 | | | | | 202,000 | | | | | 12,200 | | | | | 1,086,675 | | | ||||||||||||||||||||||||||||||||||||||||||||||||||
| | | 2021 | | | | | 395,000 | | | | | — | | | | | 552,376 | | | | | 931,613 | | | | | 190,864 | | | | | 11,600 | | | | | 2,081,452 | | | ||||||||||||||||||||||||||||||||||||||||||||||||||||
| | | 2020 | | | | | 45,577 | | | | | 100,000 | | | | | 100,000 | | | | | 1,517,540 | | | | | 49,375 | | | | | 7,125 | | | | | 1,819,617 | | | ||||||||||||||||||||||||||||||||||||||||||||||||||||
Jennifer Lee Executive Vice President, Head of North America | | | | | 2023 | | | | | 464,731 | | | | | 493,668 | | | | | 885,405 | | | | | 246,000 | | | | | 16,406 | | | | | 2,106,210 | | | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| | | 2022 | | | | | 430,000 | | | | | 93,500 | | | | | 348,975 | | | | | 202,000 | | | | | 12,200 | | | | | 1,086,675 | | | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| | | 2021 | | | | | 395,000 | | | | | 552,376 | | | | | 931,613 | | | | | 190,864 | | | | | 11,600 | | | | | 2,081,453 | | | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Yann Mazabraud(5) Executive Vice President, Head of International | | | | | 2023 | | | | | 448,848 | | | | | 805,100 | | | | | — | | | | | 238,688 | | | | | 249,373(6) | | | | | 1,742,009 | | | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| | | | 2022 | | | | | 380,643 | | | | | — | | | | | 93,500 | | | | | 348,975 | | | | | 202,697 | | | | | 164,090(6) | | | | | 1,189,905 | | | | | | 2022 | | | | | 380,643 | | | | | 93,500 | | | | | 348,975 | | | | | 202,697 | | | | | 164,090 | | | | | 1,189,905 | | | |||||||||||||||
| | | 2021 | | | | | 384,250 | | | | | — | | | | | 552,376 | | | | | 931,613 | | | | | 190,864 | | | | | 118,502 | | | | | 2,177,605 | | | | | | 2021 | | | | | 384,250 | | | | | 552,376 | | | | | 931,613 | | | | | 190,864 | | | | | 118,502 | | | | | 2,177,605 | | | ||||||||||||||||
Joseph Shulman Chief Technical Officer | | | | | 2022 | | | | | 410,000 | | | | | — | | | | | 72,250 | | | | | 269,663 | | | | | 186,000 | | | | | 12,200 | | | | | 950,113 | | | | | | | 2023 | | | | | 430,192 | | | | | 430,763 | | | | | 632,432 | | | | | 226,000 | | | | | 21,081 | | | | | 1,740,468 | | | |||||||||||||
| | | 2021 | | | | | 386,250 | | | | | — | | | | | 516,545 | | | | | 716,625 | | | | | 157,223 | | | | | 11,600 | | | | | 1,788,243 | | | | | | 2022 | | | | | 410,000 | | | | | 72,250 | | | | | 269,663 | | | | | 186,000 | | | | | 12,200 | | | | | 950,113 | | | ||||||||||||||||
Joseph Shulman Chief Technical Officer | | | | 2021 | | | | | 386,250 | | | | | 516,545 | | | | | 716,625 | | | | | 157,223 | | | | | 11,600 | | | | | 1,788,243 | | |
Name | | | Grant Date | | | Estimated Future Payouts Under Non-Equity Incentive Plan Awards(1) | | Estimated Future Payouts Under Equity Incentive Plan Awards | | | All Other Stock Awards: Number of Shares of Stock or Units(#) | | All Other Option Awards: Number of Securities Underlying Options(#) | | Exercise or Base Price of Option Awards ($/Sh) | | Grant Date Fair Value of Stock and Option Awards ($) | | | | Grant Date | | | Estimated Future Payouts Under Non-Equity Incentive Plan Awards(1) | | Estimated Future Payouts Under Equity Incentive Plan Awards | | | All Other Stock Awards: Number of Shares of Stock or Units(#) | | All Other Option Awards: Number of Securities Underlying Options(#) | | Exercise or Base Price of Option Awards ($/Sh) | | Grant Date Fair Value of Stock and Option Awards ($) | | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Threshold ($) | | Target ($) | | Maximum ($) | | Threshold (#) | | Target (#) | | Maximum (#) | | | Threshold ($) | | Target ($) | | Maximum ($) | | Threshold (#) | | Target (#) | | Maximum (#) | | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
David P. Meeker | | — | | | | — | | | | | 423,833 | | | | | 752,727 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | — | | | | — | | | | | 466,216 | | | | | 819,025 | | | | | — | | | | | — | | | | | — | | | | | — | | | | | — | | | | | — | | | | | — | | | ||||||||||||||||||||||||||||
| | | | 2/9/2022 | | | | ��� | | | | | | | | | | | | | | | | | | — | | | | | — | | | | | — | | | | | 510,000 | | | | $ | 6.80 | | | | $ | 2,157,300 | | | | | | 2/1/2023 | | | | | — | | | | | — | | | | | — | | | | | | | | | | | | | | | | | | | | — | | | | | 229,600 | | | | $ | 27.35 | | | | $ | 4,334,521 | | | ||||||||||||||||||||||
| | | | 2/1/2023 | | | | | — | | | | | — | | | | | — | | | | | — | | | | | — | | | | | — | | | | | 56,500 | | | | | — | | | | | — | | | | $ | 1,545,275 | | | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Hunter C. Smith | | — | | | | — | | | | | 184,000 | | | | | 326,784 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | — | | | | — | | | | | 192,000 | | | | | 337,296 | | | | | — | | | | | — | | | | | — | | | | | — | | | | | — | | | | | — | | | | | — | | | ||||||||||||||||||||||||||||
| | | | 2/9/2022 | | | | | | | | | | | | | | | | | | | | | | — | | | | | — | | | | | | | | | | 97,500 | | | | $ | 6.80 | | | | $ | 412,425 | | | | | | 2/1/2023 | | | | | — | | | | | — | | | | | — | | | | | — | | | | | — | | | | | — | | | | | — | | | | | 53,600 | | | | $ | 27.35 | | | | $ | 1,011,892 | | | ||||||||||||||||||||||
| | | | 2/9/2022 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | 16,250 | | | | | — | | | | | — | | | | $ | 110,500 | | | | | | 2/1/2023 | | | | | — | | | | | — | | | | | — | | | | | — | | | | | — | | | | | — | | | | | 19,700 | | | | | — | | | | | — | | | | $ | 538,795 | | | ||||||||||||||||||||||
Jennifer Chien | | — | | | | — | | | | | 172,000 | | | | | 305,472 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Jennifer Lee | | — | | | | — | | | | | 189,200 | | | | | 332,377 | | | | | — | | | | | — | | | | | — | | | | | — | | | | | — | | | | | — | | | | | — | | | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| | | | 2/9/2022 | | | | | | | | | | | | | | | | | | | | | | — | | | | | — | | | | | | | | | | 82,500 | | | | $ | 6.80 | | | | $ | 348,975 | | | | | | 2/1/2023 | | | | | — | | | | | — | | | | | — | | | | | — | | | | | — | | | | | — | | | | | — | | | | | 46,900 | | | | $ | 27.35 | | | | $ | 885,405 | | | ||||||||||||||||||||||
| | | | 2/9/2022 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | 13,750 | | | | | — | | | | | — | | | | $ | 93,500 | | | | | | 2/1/2023 | | | | | — | | | | | — | | | | | — | | | | | — | | | | | — | | | | | — | | | | | 18,050 | | | | | — | | | | | — | | | | $ | 493,668 | | | ||||||||||||||||||||||
Yann Mazabraud | | — | | | | — | | | | | 172,000 | | | | | 305,472 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | — | | | | — | | | | | 185,330 | | | | | 325,578 | | | | | — | | | | | — | | | | | — | | | | | — | | | | | — | | | | | — | | | | | — | | | ||||||||||||||||||||||||||||
| | | | 2/9/2022 | | | | | | | | | | | | | | | | | | | | | | — | | | | | — | | | | | | | | | | 82,500 | | | | $ | 6.80 | | | | $ | 348,975 | | | | | | 2/1/2023 | | | | | — | | | | | — | | | | | — | | | | | | | | | | | | | | | | | | | | 41,500 | | | | | — | | | | | — | | | | $ | 805,100 | | | ||||||||||||||||||||||
| | | | 2/9/2022 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | 13,750 | | | | | — | | | | | — | | | | $ | 93,500 | | | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Joseph Shulman | | — | | | | — | | | | | 164,000 | | | | | 291,264 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | — | | | | — | | | | | 174,000 | | | | | 305,675 | | | | | — | | | | | — | | | | | — | | | | | — | | | | | 33,500 | | | | $ | 27.35 | | | | $ | 632,432 | | | ||||||||||||||||||||||||||||
| | | | 2/9/2022 | | | | | | | | | | | | | | | | | | | | | | — | | | | | — | | | | | | | | | | 63,750 | | | | $ | 6.80 | | | | $ | 269,663 | | | | | | 2/1/2023 | | | | | — | | | | | — | | | | | — | | | | | — | | | | | — | | | | | — | | | | | 15,750 | | | | | — | | | | | — | | | | $ | 430,763 | | | ||||||||||||||||||||||
| | | | 2/9/2022 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | 10,625 | | | | | — | | | | | — | | | | $ | 72,250 | | |
| | Option Awards (2) | | Stock Awards | | | Option Awards(2) | | Stock Awards | | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Name | | Vesting Commencement Date | | Number of Securities Underlying Unexercised Options (#) Exercisable | | Number of Securities Underlying Unexercised Options (#) Unexercisable | | Option Exercise Price ($) | | Option Expiration Date | | Number of Shares or Units of Stock That Have Not Vested (#) | | Market Value of Shares or Units of Stock That Have Not Vested ($)(1) | | Equity Incentive Plan Awards: Number of Unearned Shares, Units or Other Rights That Have Not Vested (#) | | Equity Incentive Plan Awards: Market or Payout Value of Unearned Shares, Units or Other Rights That Have Not Vested ($) | | | Vesting Commencement Date | | Number of Securities Underlying Unexercised Options (#) Exercisable | | Number of Securities Underlying Unexercised Options (#) Unexercisable | | Option Exercise Price ($) | | Option Expiration Date | | Number of Shares or Units of Stock That Have Not Vested (#) | | Market Value of Shares or Units of Stock That Have Not Vested ($)(1) | | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
David P. Meeker, M.D. | | | | 11/17/2015(2) | | | | | 43,621 | | | | | — | | | | $ | 4.59 | | | | | 11/16/2025 | | | | | | | | | | | | | | | | | | | | | | | | | | | 11/17/2015(2) | | | | | 43,620 | | | | | — | | | | $ | 4.59 | | | | | 11/16/2025 | | | | | | | | | | | | | |||||||||||||||
| | | | 1/6/2017(2) | | | | | 65,430 | | | | | — | | | | $ | 6.05 | | | | | 02/07/2027 | | | | | | | | | | | | | | | | | | | | | | | ||||||||||||||||||||||||||||||||||||||||||||||||||||
| | | | 6/6/2018(3) | | | | | 10,000 | | | | | — | | | | $ | 34.89 | | | | | 06/05/2028 | | | | | | | | | | | | | | | | | | | | | | | ||||||||||||||||||||||||||||||||||||||||||||||||||||
| | | | 6/19/2019(3) | | | | | 15,000 | | | | | — | | | | $ | 22.93 | | | | | 06/18/2029 | | | | | | | | | | | | | | | | | | | | | | | ||||||||||||||||||||||||||||||||||||||||||||||||||||
| | | | 6/17/2020(3) | | | | | 18,500 | | | | | — | | | | $ | 21.37 | | | | | 06/16/2030 | | | | | | | | | | | | | | | | | | | | | | | ||||||||||||||||||||||||||||||||||||||||||||||||||||
| | | | 7/20/2020(4) | | | | | 506,250 | | | | | 393,750 | | | | $ | 22.53 | | | | | 07/19/2030 | | | | | | | | | | | | | | | | | | | | | | | ||||||||||||||||||||||||||||||||||||||||||||||||||||
| | | | 2/11/2021(5) | | | | | 96,250 | | | | | 123,750 | | | | $ | 30.66 | | | | | 02/10/2031 | | | | | | | | | | | | | | | | | | | | | | | ||||||||||||||||||||||||||||||||||||||||||||||||||||
| | | | 11/9/2021(6) | | | | | | | | | | | | | | | | | | | | | | | | | 32,992 | | | | | 960,727 | | | | | 43,990 | | | | | 1,280,974 | | | ||||||||||||||||||||||||||||||||||||||||||||||||||||
| | | | 2/9/2022(5) | | | | | 95,625 | | | | | 414,375 | | | | $ | 6.80 | | | | | 02/08/2032 | | | | | | | | | | | | | | | | | | | | | | | ||||||||||||||||||||||||||||||||||||||||||||||||||||
David P. Meeker, M.D. | | | | 1/6/2017(2) | | | | | 65,430 | | | | | — | | | | $ | 6.05 | | | | | 02/07/2027 | | | | | | | | | | | | | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| | | 6/6/2018(3) | | | | | 10,000 | | | | | — | | | | $ | 34.89 | | | | | 06/05/2028 | | | | | | | | | | | | | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| | | | 6/19/2019(3) | | | | | 15,000 | | | | | — | | | | $ | 22.93 | | | | | 06/18/2029 | | | | | | | | | | | | | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| | | 6/17/2020(3) | | | | | 18,500 | | | | | — | | | | $ | 21.37 | | | | | 06/16/2030 | | | | | | | | | | | | | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| | | 7/20/2020(8) | | | | | 731,250 | | | | | 168,750 | | | | $ | 22.53 | | | | | 07/19/2030 | | | | | | | | | | | | | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| | | 2/11/2021(5) | | | | | 151,250 | | | | | 68,750 | | | | $ | 30.66 | | | | | 02/10/2031 | | | | | | | | | | | | | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| | | 11/9/2021(6) | | | | | | | | | | | | | | | | | | | | | | | | | 99,000 | | | | | 4,551,030 | | | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| | | 2/9/2022(5) | | | | | 223,125 | | | | | 286,875 | | | | $ | 6.80 | | | | | 02/08/2032 | | | | | | | | | | | | | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| | | 2/1/2023(5) | | | | | 43,050 | | | | | 186,550 | | | | $ | 27.35 | | | | | 2/1/2033 | | | | | | | | | | | | | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| | | 2/1/2023(7) | | | | | | | | | | | | | | | | | | | | | | | | | 56,500 | | | | | 2,597,305 | | | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| | | 7/31/2017(4) | | | | | 163,094 | | | | | — | | | | $ | 6.88 | | | | | 08/08/2027 | | | | | | | | | | | | | | | | | | | | | | | | | | 7/31/2017(4) | | | | | 201,744 | | | | | — | | | | $ | 6.88 | | | | | 08/08/2027 | | | | | | | | | | | | | |||||||||||||||||
| | | | 2/14/2018(5) | | | | | 61,000 | | | | | — | | | | $ | 25.79 | | | | | 02/13/2028 | | | | | | | | | | | | | | | | | | | | | | | ||||||||||||||||||||||||||||||||||||||||||||||||||||
| | | | 5/13/2019(5) | | | | | 65,625 | | | | | 4,375 | | | | $ | 29.78 | | | | | 02/12/2029 | | | | | | | | | | | | | | | | | | | | | | | ||||||||||||||||||||||||||||||||||||||||||||||||||||
| | | | 5/14/2020(5) | | | | | 56,375 | | | | | 25,625 | | | | $ | 17.87 | | | | | 02/13/2030 | | | | | | | | | | | | | | | | | | | | | | | ||||||||||||||||||||||||||||||||||||||||||||||||||||
| | | | 7/20/2020(5) | | | | | 7,812 | | | | | 17,188 | | | | $ | 22.53 | | | | | 07/16/2030 | | | | | | | | | | | | | | | | | | | | | | | ||||||||||||||||||||||||||||||||||||||||||||||||||||
| | | | 2/11/2021(5) | | | | | 24,609 | | | | | 31,641 | | | | $ | 30.66 | | | | | 02/10/2031 | | | | | | | | | | | | | | | | | | | | | | | ||||||||||||||||||||||||||||||||||||||||||||||||||||
| | | | 2/11/2021(7) | | | | | | | | | | | | | | | | | | | | | | | | | 7,031 | | | | | 204,743 | | | | | | | | | | | | | ||||||||||||||||||||||||||||||||||||||||||||||||||||
| | | | 11/9/2021(6) | | | | | | | | | | | | | | | | | | | | | | | | | 11,248 | | | | | 327,542 | | | | | 14,996 | | | | | 436,684 | | | ||||||||||||||||||||||||||||||||||||||||||||||||||||
| | | | 2/9/2022(5) | | | | | 18,281 | | | | | 79,219 | | | | $ | 6.80 | | | | | 02/08/2032 | | | | | | | | | | | | | | | | | | | | | | | ||||||||||||||||||||||||||||||||||||||||||||||||||||
| | | | 2/11/2022(7) | | | | | | | | | | | | | | | | | | | | | | | | | 16,250 | | | | | 473,200 | | | | | | | | | | | | | ||||||||||||||||||||||||||||||||||||||||||||||||||||
Hunter C. Smith | | | | | 2/14/2018(5) | | | | | 61,000 | | | | | — | | | | $ | 25.79 | | | | | 02/13/2028 | | | | | | | | | | | | | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| | | 2/13/2019(5) | | | | | 70,000 | | | | | — | | | | $ | 29.78 | | | | | 02/12/2029 | | | | | | | | | | | | | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| | | 2/14/2020(5) | | | | | 76,875 | | | | | 5,125 | | | | $ | 17.87 | | | | | 02/13/2030 | | | | | | | | | | | | | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| | | 7/20/2020(5) | | | | | 20,312 | | | | | 4,688 | | | | $ | 22.53 | | | | | 07/19/2030 | | | | | | | | | | | | | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| | | 2/11/2021(5) | | | | | 38,672 | | | | | 17,578 | | | | $ | 30.66 | | | | | 02/10/2031 | | | | | | | | | | | | | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| | | 2/11/2021(7) | | | | | | | | | | | | | | | — | | | | | — | | | | | 4,687 | | | | | 215,461 | | | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| | | 11/9/2021(6) | | | | | | | | | | | | | | | | | | | | | | | | | 33,750 | | | | | 1,551,488 | | | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| | | 2/9/2022(5) | | | | | 42,656 | | | | | 54,844 | | | | $ | 6.80 | | | | | 02/08/2032 | | | | | | | | | | | | | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| | | 2/9/2022(7) | | | | | | | | | | | | | | | — | | | | | — | | | | | 12,187 | | | | | 560,236 | | | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| | | 2/1/2023(5) | | | | | 10,050 | | | | | 43,550 | | | | $ | 27.35 | | | | | 2/1/2033 | | | | | | | | | | | | | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| | | 2/1/2023(7) | | | | | | | | | | | | | | | | | | | | | | | | | 19,700 | | | | | 905,609 | | | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| | | 10/5/2020(8) | | | | | 50,000 | | | | | 50,000 | | | | $ | 22.28 | | | | | 10/04/2030 | | | | | | | | | | | | | | | | | | | | | | | | | | 10/5/2020(8) | | | | | 75,000 | | | | | 25,000 | | | | $ | 22.28 | | | | | 10/04/2030 | | | | | | | | | | | | | |||||||||||||||||
| | | | 2/11/2021(5) | | | | | 21,328 | | | | | 27,422 | | | | $ | 30.66 | | | | | 02/10/2031 | | | | | | | | | | | | | | | | | | | | | | | ||||||||||||||||||||||||||||||||||||||||||||||||||||
| | | | 2/11/2021(7) | | | | | | | | | | | | | | | | | | | | | | | | | 6,093 | | | | | 177,428 | | | | | | | | | | | | | ||||||||||||||||||||||||||||||||||||||||||||||||||||
| | | | 11/9/2021(6) | | | | | | | | | | | | | | | | | | | | | | | | | 11,248 | | | | | 327,542 | | | | | 14,996 | | | | | 436,684 | | | ||||||||||||||||||||||||||||||||||||||||||||||||||||
| | | | 2/9/2022(5) | | | | | 15,469 | | | | | 67,031 | | | | $ | 6.80 | | | | | 02/08/2032 | | | | | | | | | | | | | | | | | | | | | | | ||||||||||||||||||||||||||||||||||||||||||||||||||||
| | | | 2/9/2022(7) | | | | | | | | | | | | | | | | | | | | | | | | | 13,760 | | | | | 400,691 | | | | | | | | | | | | | ||||||||||||||||||||||||||||||||||||||||||||||||||||
Jennifer Chien | | | | 11/9/2020(8) | | | | | 50,000 | | | | | 50,000 | | | | $ | 24.29 | | | | | 11/08/2030 | | | | | | | | | | | | | | | | | | | | | | | ||||||||||||||||||||||||||||||||||||||||||||||||||||
| | | | 2/11/2021(5) | | | | | 21,328 | | | | | 27,422 | | | | $ | 30.66 | | | | | 02/10/2031 | | | | | | | | | | | | | | | | | | | | | | | ||||||||||||||||||||||||||||||||||||||||||||||||||||
| | | | 2/11/2021(7) | | | | | | | | | | | | | | | | | | | | | | | | | 6,093 | | | | | 177,428 | | | | | | | | | | | | | ||||||||||||||||||||||||||||||||||||||||||||||||||||
| | | | 11/9/2021(6) | | | | | | | | | | | | | | | | | | | | | | | | | 11,248 | | | | | 327,542 | | | | | 14,996 | | | | | 436,684 | | | ||||||||||||||||||||||||||||||||||||||||||||||||||||
| | | | 2/9/2022(5) | | | | | 15,469 | | | | | 67,031 | | | | $ | 6.80 | | | | | 02/08/2032 | | | | | | | | | | | | | | | | | | | | | | | ||||||||||||||||||||||||||||||||||||||||||||||||||||
| | | | 2/9/2022(7) | | | | | | | | | | | | | | | | | | | | | | | | | 13,760 | | | | | 400,691 | | | | | | | | | | | | | ||||||||||||||||||||||||||||||||||||||||||||||||||||
Yann Mazabraud | | | | | 2/11/2021(5) | | | | | 33,515 | | | | | 15,235 | | | | $ | 30.66 | | | | | 02/10/2031 | | | | | | | | | | | | | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| | | 2/11/2021(7) | | | | | | | | | | | | | | | — | | | | | — | | | | | 4,062 | | | | | 186,730 | | | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| | | 11/9/2021(6) | | | | | | | | | | | | | | | | | | | | | | | | | 33,750 | | | | | 1,551,488 | | | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| | | 2/9/2022(5) | | | | | 36,094 | | | | | 46,406 | | | | $ | 6.80 | | | | | 02/08/2032 | | | | | | | | | | | | | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| | | 2/9/2022(7) | | | | | | | | | | | | | | | — | | | | | — | | | | | 10,312 | | | | | 474,043 | | | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| | | 4/14/2023(7) | | | | | | | | | | | | | | | | | | | | | | | | | 41,500 | | | | | 1,907,755 | | | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| | | 11/9/2020(8) | | | | | 75,000 | | | | | 25,000 | | | | $ | 24.29 | | | | | 11/08/2030 | | | | | | | | | | | | | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Jennifer Lee | | | | | 2/11/2021(5) | | | | | 33,515 | | | | | 15,235 | | | | $ | 30.66 | | | | | 02/10/2031 | | | | | | | | | | | | | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| | | 2/11/2021(7) | | | | | | | | | | | | | | | — | | | | | — | | | | | 4,062 | | | | | 186,730 | | | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| | | 11/9/2021(6) | | | | | | | | | | | | | | | | | | | | | | | | | 33,750 | | | | | 1,551,488 | | | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| | | 2/9/2022(5) | | | | | 36,094 | | | | | 46,406 | | | | $ | 6.80 | | | | | 02/08/2032 | | | | | | | | | | | | | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| | | 2/9/2022(7) | | | | | | | | | | | | | | | — | | | | | — | | | | | 10,312 | | | | | 474,043 | | | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| | | 2/1/2023(5) | | | | | 8,794 | | | | | 38,106 | | | | | 27.35 | | | | | 2/1/2033 | | | | | | | | | | | | | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| | | 2/1/2023(7) | | | | | | | | | | | | | | | | | | | | | | | | | 18,050 | | | | | 829,759 | | | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| | | 7/27/2020(8) | | | | | 47,813 | | | | | 37,187 | | | | $ | 21.38 | | | | | 07/26/2030 | | | | | | | | | | | | | | | | | | | | | | | | | | 7/27/2020(8) | | | | | 69,063 | | | | | 15,937 | | | | $ | 21.38 | | | | | 07/26/2030 | | | | | | | | | | | | | |||||||||||||||||
| | | | 2/11/2021(5) | | | | | 16,406 | | | | | 21,094 | | | | $ | 30.66 | | | | | 02/10/2031 | | | | | | | | | | | | | | | | | | | | | | | ||||||||||||||||||||||||||||||||||||||||||||||||||||
| | | | 2/11/2021(7) | | | | | | | | | | | | | | | | | | | | | | | | | 4,687 | | | | | 136,485 | | | | | | | | | | | | | ||||||||||||||||||||||||||||||||||||||||||||||||||||
| | | | 11/9/2021(6) | | | | | | | | | | | | | | | | | | | | | | | | | 11,248 | | | | | 327,542 | | | | | 14,996 | | | | | 436,684 | | | ||||||||||||||||||||||||||||||||||||||||||||||||||||
| | | | 2/9/2022(5) | | | | | 11,963 | | | | | 51,797 | | | | $ | 6.80 | | | | | 02/08/2032 | | | | | | | | | | | | | | | | | | | | | | | ||||||||||||||||||||||||||||||||||||||||||||||||||||
| | | | 2/9/2022(7) | | | | | | | | | | | | | | | | | | | | | | | | | 10,625 | | | | | 309,400 | | | | | | | | | | | | | ||||||||||||||||||||||||||||||||||||||||||||||||||||
Joseph Shulman | | | | | 2/11/2021(5) | | | | | 25,781 | | | | | 11,719 | | | | $ | 30.66 | | | | | 02/10/2031 | | | | | | | | | | | | | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| | | 2/11/2021(7) | | | | | | | | | | | | | | | — | | | | | — | | | | | 3,124 | | | | | 143,610 | | | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| | | 11/9/2021(6) | | | | | | | | | | | | | | | | | | | | | | | | | 33,750 | | | | | 1,551,488 | | | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| | | 2/9/2022(5) | | | | | 27,890 | | | | | 35,860 | | | | $ | 6.80 | | | | | 02/08/2032 | | | | | | | | | | | | | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| | | 2/9/2022(7) | | | | | | | | | | | | | | | — | | | | | — | | | | | 7,968 | | | | | 366,289 | | | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| | | 2/1/2023(5) | | | | | 6,281 | | | | | 27,219 | | | | | 27.35 | | | | | 2/1/2033 | | | | | | | | | | | | | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| | | 2/1/2023(7) | | | | | | | | | | | | | | | | | | | | | | | | | 15,750 | | | | | 724,028 | | |
| | Option Awards | | Stock Awards | | | Option Awards | | Stock Awards | | ||||||||||||||||||||||||||||||||||||||||
Name | | Number of Shares Acquired on Exercise (#) | | Value Realized on Exercise(1) ($) | | Number of Shares Acquired on Vesting (#) | | Value Realized on Vesting(2) ($) | | | Number of Shares Acquired on Exercise (#) | | Value Realized on Exercise(1) ($) | | Number of Shares Acquired on Vesting (#) | | Value Realized on Vesting(2) ($) | | ||||||||||||||||||||||||||||||||
David P. Meeker | | | | — | | | | | — | | | | | — | | | | | — | | | | | | — | | | | | — | | | | | — | | | | | — | | | ||||||||
Hunter C. Smith | | | | — | | | | | — | | | | | 27,344 | | | | | 118,119 | | | | | | 62,500 | | | | $ | 1,884,726 | | | | | 6,407 | | | | $ | 177,475 | | | ||||||||
Jennifer Chien | | | | — | | | | | — | | | | | 2,032 | | | | | 12,456 | | | |||||||||||||||||||||||||||||
Jennifer Lee | | | | 36,088 | | | | $ | 779,081 | | | | | 5,469 | | | | $ | 151,496 | | | |||||||||||||||||||||||||||||
Yann Mazabraud | | | | — | | | | | — | | | | | 2,032 | | | | | 12,456 | | | | | | — | | | | | — | | | | | 5,469 | | | | $ | 151,496 | | | ||||||||
Joe Shulman | | | | — | | | | | — | | | | | 1,563 | | | | | 9,581 | | | | | | 37,090 | | | | $ | 968,126 | | | | | 4,220 | | | | $ | 116,897 | | |
Name | | Benefit | | Termination Without Cause or for Good Reason / Cause (no Change in Control) ($) | | Change in Control (no Termination) ($)(1) | | Termination Without Cause or for Good Reason / Cause in Connection with a Change in Control ($) | | | Benefit | | Termination Without Cause or for Good Reason / Cause (no Change in Control) ($) | | Change in Control (no Termination) ($)(1) | | Termination Without Cause or for Good Reason / Cause in Connection with a Change in Control ($)(2) | | ||||||||||||||||||||||||||
David P. Meeker | | Cash | | | | 652,050 | | | | | — | | | | | 978,075 | | | | Cash | | | | 717,254 | | | | | — | | | | | 1,775,207 | | | ||||||||
| | Equity Acceleration(2) | | | | — | | | | | 14,085,364 | | | | | 14,085,364 | | | | Equity Acceleration | | | | — | | | | | 4,551,030 | | | | | 28,383,494 | | | ||||||||
| | Continued Healthcare | | | | 20,741 | | | | | — | | | | | 31,162 | | | | Continued Healthcare | | | | 26,679 | | | | | — | | | | | 40,019 | | | ||||||||
| | Total(3) | | | | 672,824 | | | | | 14,085,364 | | | | | 15,094,601 | | | | Total(3) | | | | 743,933 | | | | | 4,551,030 | | | | | 30,198,720 | | | ||||||||
Hunter C. Smith | | Cash | | | | 345,000 | | | | | — | | | | | 644,000 | | | | Cash | | | | 360,000 | | | | | — | | | | | 672,000 | | | ||||||||
| | Equity Acceleration(2) | | | | — | | | | | 3,611,886 | | | | | 3,611,886 | | | | Equity Acceleration | | | | — | | | | | 1,551,488 | | | | | 7,262,176 | | | ||||||||
| | Continued Healthcare | | | | 21,114 | | | | | — | | | | | 28,153 | | | | Continued Healthcare | | | | 18,933 | | | | | — | | | | | 25,244 | | | ||||||||
| | Total(3) | | | | 366,114 | | | | | 3,611,886 | | | | | 4,284,039 | | | | Total(3) | | | | 378,933 | | | | | 1,551,488 | | | | | 7,959,420 | | | ||||||||
Jennifer Chien | | Cash | | | | 322,500 | | | | | — | | | | | 602,000 | | | ||||||||||||||||||||||||||
Jennifer Lee | | Cash | | | | 354,750 | | | | | — | | | | | 662,200 | | | ||||||||||||||||||||||||||
| | Equity Acceleration(2) | | | | — | | | | | 3,079,977 | | | | | 3,079,977 | | | | Equity Acceleration | | | | — | | | | | 1,551,488 | | | | | 6,861,599 | | | ||||||||
| | Continued Healthcare | | | | — | | | | | — | | | | | — | | | | Continued Healthcare | | | | — | | | | | — | | | | | — | | | ||||||||
| | Total(3) | | | | 322,500 | | | | | 3,079,977 | | | | | 3,681,977 | | | | Total(3) | | | | 354,750 | | | | | 1,551,488 | | | | | 7,523,799 | | | ||||||||
Yann Mazabraud | | Cash | | | | 226,568 | | | | | — | | | | | 226,568 | | | | Cash | | | | 98,750 | | | | | — | | | | | 98,750 | | | ||||||||
| | Equity Acceleration(2) | | | | — | | | | | 3,180,477 | | | | | 3,180,477 | | | | Equity Acceleration | | | | — | | | | | 1,551,488 | | | | | 7,280,307 | | | ||||||||
| | All Other Payments or Benefits | | | | — | | | | | — | | | | | | | | | All Other Payments or Benefits | | | | — | | | | | — | | | | | — | | | ||||||||
| | Total(3) | | | | 226,568 | | | | | 3,180,477 | | | | | 3,407,045 | | | | Total(3) | | | | 98,750 | | | | | 1,551,488 | | | | | 7,379,057 | | | ||||||||
Joseph Shulman | | Cash | | | | 307,000 | | | | | — | | | | | 574,000 | | | | Cash | | | | 326,250 | | | | | — | | | | | 609,000 | | | ||||||||
| | Equity Acceleration | | | | — | | | | | 2,654,047 | | | | | 2,654,047 | | | | Equity Acceleration | | | | — | | | | | 1,551,488 | | | | | 5,785,261 | | | ||||||||
| | Continued Healthcare | | | | 15,581 | | | | | — | | | | | 20,774 | | | | Continued Healthcare | | | | 20,010 | | | | | — | | | | | 26,679 | | | ||||||||
| | Total(3) | | | | 322,581 | | | | | 2,654,047 | | | | | 3,248,821 | | | | Total(3) | | | | 346,260 | | | | | 1,551,488 | | | | | 6,420,940 | | |
Year | | | Summary Compensation Table (SCT) Total for PEO | | Compensation Actually Paid to PEO(3) | | Average SCT Total for Non- PEO NEOs | | Average Compensation Actually Paid to Non-PEO NEOs(3) | | | Value of Initial Fixed td00 Investment Based on: | | | | Summary Compensation Table Total for PEO ($) | | Compensation Actually Paid to PEO ($)(1) | | Average Summary Compensation Table Total for Non-PEO NEOs ($) | | Average Compensation Actually Paid to Non-PEO NEOs ($)(1) | | | Value of Initial Fixed td00 Investment Based on: | | ||||||||||||||||||||||||||||||||||||||||||||||||
| Total Shareholder Return | | Net Income | | | Total Shareholder Return ($) | | Net Income ($) | | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
2023 | | | | 7,230,457 | | | | | 19,005,711 | | | | | 1,974,174 | | | | | 4,813,432 | | | | | 154.61 | | | | | (184,678) | | | |||||||||||||||||||||||||||||||||||||||||||
2022 | | | | 3,325,758 | | | | | 23,300,503 | | | | | 1,110,454 | | | | | 4,518,216 | | | | | -2.06 | | | | | (181,119) | | | | | | 3,325,758 | | | | | 24,142,912 | | | | | 1,110,455 | | | | | 4,805,393 | | | | | -97.94 | | | | | (181,119) | | | ||||||||||||
2021 | | | | 6,458,360 | | | | | (10,456,948) | | | | | 2,069,493 | | | | | (875,147) | | | | | -66.43 | | | | | (69,612) | | | | | | 6,458,360 | | | | | (10,017,699) | | | | | 2,069,493 | | | | | (775,040) | | | | | -33.57 | | | | | (69,612) | | |
Year | | | PEO | | | Non-PEO NEOs | |
| | David P. Meeker | | | Hunter C. Smith, Jennifer Mazabraud and Joseph Shulman | | |
| | David P. Meeker | | | Hunter C. Smith, Jennifer Lee, Yann Mazabraud and Joseph Shulman | | |
2021 | | | David P. Meeker | | | Hunter C. Smith, Murray Stewart, Jennifer Lee, Yann Mazabraud and Joseph Shulman | |
| | | 2023 | | |||||||||
| | | PEO | | | Average for Other NEO’s | | ||||||
Summary Compensation Table Total | | | | | 7,230,457 | | | | | | 1,974,174 | | |
ADJUSTMENTS(a): | | | | | | | | | | | | | |
Deduction for Amounts reported under the “Stock Awards” and “Option Awards” Columns in the Summary Compensation Table(a) | | | | | (5,879,796) | | | | | | (1,199,513) | | |
Increase based on ASC 718 Fair Value of Awards Granted during Applicable FY that Remain Unvested as of Applicable FY End, determined as of Applicable FY End | | | | | 8,977,366 | | | | | | 2,036,531 | | |
Increase based on ASC 718 Fair Value of Awards Granted during Applicable FY that Vested during Applicable FY, determined as of Vesting Date | | | | | 573,865 | | | | | | 78,330 | | |
Increase/deduction for Awards Granted during Prior FY that were Outstanding and Unvested as of Applicable FY End, determined based on change in ASC 718 Fair Value from Prior FY End to Applicable FY End | | | | | 10,292,892 | | | | | | 2,225,371 | | |
Increase/deduction for Awards Granted during Prior FY that Vested During Applicable FY, determined based on change in ASC 718 Fair Value from Prior FY End to Vesting Date | | | | | (2,189,073) | | | | | | (301,461) | | |
Deduction of ASC 718 Fair Value of Awards Granted during Prior FY that were Forfeited during Applicable FY, determined as of Prior FY End | | | | | — | | | | | | — | | |
Increase based on Dividends or Other Earnings Paid during Applicable FY prior to Vesting Date | | | | | — | | | | | | — | | |
Increase based on Incremental Fair Value of Options/SARs Modified during Applicable FY | | | | | — | | | | | | — | | |
| | | 2022 | | | 2021 | | ||||||||||||||||||
| | | PEO | | | Average for Other NEO’s | | | PEO | | | Average for Other NEO’s | | ||||||||||||
Summary Compensation Table Total | | | | | 3,325,758 | | | | | | 1,110,454 | | | | | | 6,458,360 | | | | | | 2,089,178 | | |
ADJUSTMENTS(a): | | | | | | | | | | | | | | | | | | | | | | | | | |
Deduction for Amounts reported under the “Stock Awards” and “Option Awards” Columns in the Summary Compensation Table(a) | | | | | (2,157,300) | | | | | | (437,447) | | | | | | (5,369,042) | | | | | | (1,449,555) | | |
Increase based on ASC 718 Fair Value of Awards Granted during Applicable FY that Remain Unvested as of Applicable FY End, determined as of Applicable FY End | | | | | 10,482,921 | | | | | | 2,072,347 | | | | | | 1,452,839 | | | | | | 403,025 | | |
Increase based on ASC 718 Fair Value of Awards Granted during Applicable FY that Vested during Applicable FY, determined as of Vesting Date | | | | | 1,225,845 | | | | | | 196,045 | | | | | | 264,748 | | | | | | 56,509 | | |
Increase/deduction for Awards Granted during Prior FY that were Outstanding and Unvested as of Applicable FY End, determined based on change in ASC 718 Fair Value from Prior FY End to Applicable FY End | | | | | 9,759,451 | | | | | | 1,489,684 | | | | | | (9,884,565) | | | | | | (1,161,722) | | |
Increase/deduction for Awards Granted during Prior FY that Vested During Applicable FY, determined based on change in ASC 718 Fair Value from Prior FY End to Vesting Date | | | | | 663,828 | | | | | | 87,133 | | | | | | (3,379,288) | | | | | | (414,095) | | |
Deduction of ASC 718 Fair Value of Awards Granted during Prior FY that were Forfeited during Applicable FY, determined as of Prior FY End | | | | | — | | | | | | — | | | | | | — | | | | | | (398,487) | | |
Increase based on Dividends or Other Earnings Paid during Applicable FY prior to Vesting Date | | | | | — | | | | | | — | | | | | | — | | | | | | — | | |
Increase based on Incremental Fair Value of Options/ SARs Modified during Applicable FY | | | | | — | | | | | | — | | | | | | — | | | | | | — | | |
Adjustments Related to Defined Benefit and Actuarial Pension Plans | | | | | — | | | | | | — | | | | | | — | | | | | | — | | |
Compensation Actually Paid | | | | | 23,300,503 | | | | | | 4,518,216 | | | | | | (10,456,949) | | | | | | (875,147) | | |
| | | 2023 | | |||||||||
| | | PEO | | | Average for Other NEO’s | | ||||||
Adjustments Related to Defined Benefit and Actuarial Pension Plans | | | | | — | | | | | | — | | |
Compensation Actually Paid | | | | | 19,005,711 | | | | | | 4,813,432 | | |
|
Fee Category | | 2021 | | 2022 | | | 2022 | | 2023 | | ||||||||||||||||
Audit Fees | | | $ | 903,571 | | | | $ | 902,250 | | | | | $ | 902,250 | | | | $ | 1,602,092 | | | ||||
Audit Related Fees | | | | — | | | | | — | | | |||||||||||||||
Audit-Related Fees | | | | — | | | | | — | | | |||||||||||||||
Tax Fees | | | $ | 53,600 | | | | $ | 107,932 | | | | | | 107,932 | | | | | 349,950 | | | ||||
All Other Fees | | | $ | 3,600 | | | | $ | 3,600 | | | | | | 3,600 | | | | | 3,600 | | | ||||
Total Fees | | | $ | 960,771 | | | | $ | 1,013,782 | | | | | $ | 1,013,782 | | | | $ | 1,955,643 | | |
Year | | | Number of Shares | | | As a % of Outstanding Shares(1) | | | Dollar Value(2) | | |||||||||
2017 Plan | | | | | | | | | | | | | | | | | | | |
Stock Options | | | | | 6,490,000 | | | | | | 10.6% | | | | | $ | 253,174,900 | | |
Restricted Stock Units | | | | | 1,530,601 | | | | | | 2.5% | | | | | $ | 59,708,745 | | |
Shares remaining available for issuance under the 2017 Plan(3) | | | | | 5,015,248 | | | | | | 8.2% | | | | | $ | 195,644,839 | | |
| | | Number of Stock Options | | | Number of Restricted Stock Units | | ||||||
David P. Meeker, M.D. (President and Chief Executive Officer) | | | | | 2,227,530 | | | | | | 273,492 | | |
Hunter C. Smith (Chief Financial Officer) | | | | | 727,494 | | | | | | 141,722 | | |
Jennifer Chien (Executive Vice President, Head of North America) | | | | | 345,150 | | | | | | 106,922 | | |
Yann Mazabraud (Executive Vice President, Head of International) | | | | | 298,250 | | | | | | 130,172 | | |
Joseph Shulman (Chief Technical Officer) | | | | | 270,000 | | | | | | 94,122 | | |
All Current Executive Officers as a Group (5 persons) | | | | | 3,868,424 | | | | | | 746,630 | | |
All Current Non-Executive Directors as a Group (7 persons) | | | | | 666,310 | | | | | | 21,000 | | |
Stuart A. Arbuckle, director nominee | | | | | 97,500 | | | | | | 3,000 | | |
Christophe R. Jean, director nominee | | | | | 92,500 | | | | | | 3,000 | | |
| | | Number of Stock Options | | | Number of Restricted Stock Units | | ||||||
Lynn A. Tetrault, J.D., director nominee | | | | | 86,000 | | | | | | 3,000 | | |
Each associate of any directors, executive officers or nominees | | | | | — | | | | | | — | | |
Each other person who received or is to receive five percent of such options, warrants and rights | | | | | — | | | | | | — | | |
All Current Non-Executive Officer Employees as a Group (235 Persons) | | | | | 3,448,158 | | | | | | 1,908,773 | | |
Name and Address of Beneficial Owner | | | Number of Shares Beneficially Owned† | | | Percentage of Shares Beneficially Owned | | ||||||
5% or Greater Stockholders: | | | | | | | | | | | | | |
Entities affiliated with PRIMECAP Management Company(1) | | | | | 6,911,142 | | | | | | 12.2 | | |
77 E. Colorado Blvd., 11th Floor Pasadena, CA 91105 | | | | | | | | | | | | | |
Entities affiliated with Baker Bros. Advisors LP(2) | | | | | 6,354,608 | | | | | | 11.2 | | |
c/o Baker Bros. Advisors LP 860 Washington Street, 3rd Floor New York, NY 10014 | | | | | | | | | | | | | |
Entities affiliated with Federated Hermes, Inc.(3) | | | | | 6,304,482 | | | | | | 11.1 | | |
1001 Liberty Avenue Pittsburgh, PA 15222-3779 | | | | | | | | | | | | | |
Entities affiliated with RA Capital Management, LLC(4) | | | | | 5,516,067 | | | | | | 9.7 | | |
c/o RA Capital Management, LLC 200 Berkeley Street, 18th Floor, Boston, MA 02116 | | | | | | | | | | | | | |
The Goldman Sachs Group, Inc.(5) | | | | | 5,201,260 | | | | | | 9.2 | | |
200 West Street New York, NY 10282 | | | | | | | | | | | | | |
BlackRock, Inc.(6) | | | | | 3,723,714 | | | | | | 6.6 | | |
55 East 52nd Street New York, NY 10055 | | | | | | | | | | | | | |
Entities affiliated with State Street Corporation(7) | | | | | 3,180,698 | | | | | | 5.6 | | |
c/o State Street Corporation 1 Lincoln Street Boston, MA 02111 | | | | | | | | | | | | | |
Entities affiliated with New Enterprise Associates 13, L.P.(8) | | | | | 2,911,349 | | | | | | 5.1 | | |
New Enterprise Associates 1954 Greenspring Drive, Suite 600 Timonium, MD 21093 | | | | | | | | | | | | | |
Directors and Named Executive Officers: | | | | | | | | | | | | | |
David P. Meeker, M.D.(9) | | | | | 1,202,907 | | | | | | 2.1 | | |
Hunter C. Smith(10) | | | | | 541,420 | | | | | | * | | |
Jennifer Chien(11) | | | | | 124,589 | | | | | | * | | |
Yann Mazabraud(12) | | | | | 119,529 | | | | | | * | | |
Joseph Shulman(13) | | | | | 105,287 | | | | | | * | | |
Stuart A. Arbuckle(14) | | | | | 83,500 | | | | | | * | | |
Name and Address of Beneficial Owner | | | Number of Shares Beneficially Owned† | | | Percentage of Shares Beneficially Owned | | ||||||
5% or Greater Stockholders: | | | | | | | | | | | | | |
Entities affiliated with PRIMECAP Management Company(1) | | | | | 8,052,648 | | | | | | 13.2 | | |
77 E. Colorado Blvd., 11th Floor Pasadena, CA 91105 | | | | | | | | | | | | | |
Entities affiliated with Baker Bros. Advisors LP(2) | | | | | 6,398,365 | | | | | | 10.5 | | |
c/o Baker Bros. Advisors LP 860 Washington Street, 3rd Floor New York, NY 10014 | | | | | | | | | | | | | |
BlackRock, Inc.(3) | | | | | 6,351,750 | | | | | | 10.4 | | |
55 East 52nd Street New York, NY 10055 | | | | | | | | | | | | | |
Entities affiliated with RA Capital Management, LLC(4) | | | | | 5,330,412 | | | | | | 8.7 | | |
c/o RA Capital Management, LLC 200 Berkeley Street, 18th Floor, Boston, MA 02116 | | | | | | | | | | | | | |
Entities affiliated with Perceptive Advisors LLC.(5) | | | | | 5,143,575 | | | | | | 8.4 | | |
51 Astor Place, 10th Floor New York, NY 10003 | | | | | | | | | | | | | |
The Goldman Sachs Group, Inc.(6) | | | | | 4,998,761 | | | | | | 8.2 | | |
200 West Street New York, NY 10282 | | | | | | | | | | | | | |
Entities affiliated with The Vanguard Group(7) | | | | | 3,226,938 | | | | | | 5.3 | | |
100 Vanguard Blvd. Malvern, PA 19355 | | | | | | | | | | | | | |
Directors and Named Executive Officers: | | | | | | | | | | | | | |
David P. Meeker, M.D.(8) | | | | | 1,724,467 | | | | | | 2.8 | | |
Hunter C. Smith(9) | | | | | 557,290 | | | | | | * | | |
Yann Mazabraud(10) | | | | | 218,760 | | | | | | * | | |
Jennifer Lee(11) | | | | | 163,122 | | | | | | * | | |
Joseph Shulman(12) | | | | | 53,404 | | | | | | * | | |
Stuart A. Arbuckle(13) | | | | | 100,500 | | | | | | * | | |
Camille L. Bedrosian, M.D.(14) | | | | | 89,000 | | | | | | * | | |
Jennifer Good(15) | | | | | 100,500 | | | | | | * | | |
Christophe R. Jean(16) | | | | | 95,500 | | | | | | * | | |
Edward T. Mathers(17) | | | | | 101,271 | | | | | | * | | |
David W.J. McGirr(18) | | | | | 182,741 | | | | | | * | | |
Lynn A. Tetrault, J.D.(19) | | | | | 89,000 | | | | | | * | | |
All executive officers and directors as a group (13 persons)(20) | | | | | 3,586,156 | | | | | | 5.6 | | |
Name and Address of Beneficial Owner | | | Number of Shares Beneficially Owned† | | | Percentage of Shares Beneficially Owned | | ||||||
Camille L. Bedrosian, M.D.(15) | | | | | 59,790 | | | | | | * | | |
Jennifer Good(16) | | | | | 83,500 | | | | | | * | | |
Christophe R. Jean(17) | | | | | 78,500 | | | | | | * | | |
Edward T. Mathers(18) | | | | | 84,271 | | | | | | * | | |
David W.J. McGirr(19) | | | | | 165,741 | | | | | | * | | |
Lynn A. Tetrault, J.D.(20) | | | | | 59,790 | | | | | | * | | |
All executive officers and directors as a group (13 persons)(21) | | | | | 2,768,857 | | | | | | 4.7 | | |
Participants | | | Total Shares Purchased | | | Aggregate Purchase Price (in thousands) | | ||||||
Greater than 5% Stockholders(1) | | | | | | | | | | | | | |
Entities affiliated with Perceptive Advisors LLC | | | | | 90,000 | | | | | $ | 90,000 | | |
Entities affiliated with Baker Bros. Advisors LP | | | | | 60,000 | | | | | $ | 60,000 | | |
| | | | | A-2 | | | |
| | | | | A-2 | | | |
| | | | | A-4 | | | |
| | | | | A-5 | | | |
| | | | | A-6 | | | |
| | | | | A-6 | | | |
| | | | | A-7 | | | |
| | | | | A-12 | | | |
| | | | | A-14 | | | |
| | | | | A-15 | | | |
| | | | | A-17 | | | |
| | | | | A-17 | | | |
| | | | | A-17 | | | |
| | | | | A-17 | | | |
| | | | | A-18 | | | |
| | | | | A-18 | | | |
| | | | | A-19 | | | |
| | | | | A-19 | | | |
| | | | | A-19 | | |